GlassScriptPhysician profile
Seena Monjazeb
NPI 1558898395
$7,528.15
in general payments reported to CMS, 2019-2025
23 companies · $4,784 in 2025
The $4,784 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.00 · 2021: $136 · 2022: $322 · 2023: $835 · 2024: $1,400 · 2025: $4,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,595 · Consulting Fee: $1,650 · Travel and Lodging: $603 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,594.61 |
| Consulting Fee | $1,650.00 |
| Travel and Lodging | $602.83 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,788.64 | 2024-2025 | Zoryve |
| Genzyme Corporation | $743.79 | 2023-2025 | |
| Abbvie INC. | $740.15 | 2021-2025 | |
| Janssen Biotech, INC. | $725.48 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $401.42 | 2022-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $379.72 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $321.15 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $243.23 | 2025 | Ebglyss, Taltz |
| Incyte Corporation | $206.29 | 2024-2025 | Opzelura |
| Revance Therapeutics, INC. | $205.90 | 2025 | Daxxify |
| Amgen INC. | $188.46 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $93.90 | 2023-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $89.75 | 2023-2025 | Nemluvio, Oracea, Aklief |
| Pfizer INC. | $86.13 | 2025 | |
| Mallinckrodt Hospital Products INC. | $64.02 | 2025 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.79 | 2025 | |
| Vyne Pharmaceuticals INC. | $50.00 | 2020 | |
| Springworks Therapeutics, INC. | $38.68 | 2025 | Gomekli |
| Ucb, INC. | $34.20 | 2022 | |
| Biofrontera INC. | $26.36 | 2025 | |
| Merz North America, INC. | $20.31 | 2023 | Xeomin |
| Strata Skin Sciences, INC. | $15.17 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $8.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seena Monjazeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.